JPWO2021255459A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021255459A5 JPWO2021255459A5 JP2022577444A JP2022577444A JPWO2021255459A5 JP WO2021255459 A5 JPWO2021255459 A5 JP WO2021255459A5 JP 2022577444 A JP2022577444 A JP 2022577444A JP 2022577444 A JP2022577444 A JP 2022577444A JP WO2021255459 A5 JPWO2021255459 A5 JP WO2021255459A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cpgs
- cancer
- assay
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 279
- 201000011510 cancer Diseases 0.000 claims description 264
- 238000003556 assay Methods 0.000 claims description 205
- 230000011987 methylation Effects 0.000 claims description 97
- 238000007069 methylation reaction Methods 0.000 claims description 97
- 206010008263 Cervical dysplasia Diseases 0.000 claims description 96
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 claims description 96
- 230000035945 sensitivity Effects 0.000 claims description 64
- 206010014733 Endometrial cancer Diseases 0.000 claims description 52
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 52
- 239000002773 nucleotide Substances 0.000 claims description 45
- 125000003729 nucleotide group Chemical group 0.000 claims description 45
- 238000012360 testing method Methods 0.000 claims description 27
- 239000000523 sample Substances 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 23
- 238000011282 treatment Methods 0.000 claims description 20
- 101100288015 Arabidopsis thaliana HSK gene Proteins 0.000 claims description 10
- 101150000533 CCM1 gene Proteins 0.000 claims description 10
- 101100273578 Schizosaccharomyces japonicus (strain yFS275 / FY16936) dmr1 gene Proteins 0.000 claims description 10
- 101100273579 Schizosaccharomyces pombe (strain 972 / ATCC 24843) ppr3 gene Proteins 0.000 claims description 10
- 238000012216 screening Methods 0.000 claims description 10
- 238000002604 ultrasonography Methods 0.000 claims description 8
- 238000002573 colposcopy Methods 0.000 claims description 7
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 7
- BLQMCTXZEMGOJM-UHFFFAOYSA-N 5-carboxycytosine Chemical compound NC=1NC(=O)N=CC=1C(O)=O BLQMCTXZEMGOJM-UHFFFAOYSA-N 0.000 claims description 6
- 201000003914 endometrial carcinoma Diseases 0.000 claims description 6
- 238000013178 mathematical model Methods 0.000 claims description 6
- 208000004548 serous cystadenocarcinoma Diseases 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 claims description 4
- RYVNIFSIEDRLSJ-UHFFFAOYSA-N 5-(hydroxymethyl)cytosine Chemical compound NC=1NC(=O)N=CC=1CO RYVNIFSIEDRLSJ-UHFFFAOYSA-N 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 208000005431 Endometrioid Carcinoma Diseases 0.000 claims description 4
- 208000009956 adenocarcinoma Diseases 0.000 claims description 4
- 208000009060 clear cell adenocarcinoma Diseases 0.000 claims description 4
- 230000002357 endometrial effect Effects 0.000 claims description 4
- 208000028730 endometrioid adenocarcinoma Diseases 0.000 claims description 4
- 210000004696 endometrium Anatomy 0.000 claims description 4
- 238000012544 monitoring process Methods 0.000 claims description 4
- 201000010879 mucinous adenocarcinoma Diseases 0.000 claims description 4
- 210000001672 ovary Anatomy 0.000 claims description 4
- 230000003647 oxidation Effects 0.000 claims description 4
- 238000007254 oxidation reaction Methods 0.000 claims description 4
- 238000009595 pap smear Methods 0.000 claims description 4
- 239000000583 progesterone congener Substances 0.000 claims description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 4
- 230000005945 translocation Effects 0.000 claims description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 3
- 239000003886 aromatase inhibitor Substances 0.000 claims description 3
- 229940046844 aromatase inhibitors Drugs 0.000 claims description 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 3
- 229960003105 metformin Drugs 0.000 claims description 3
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 claims description 3
- 230000004580 weight loss Effects 0.000 claims description 3
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims description 2
- 101100223980 Arabidopsis thaliana DMR6 gene Proteins 0.000 claims description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 2
- 208000007033 Dysgerminoma Diseases 0.000 claims description 2
- 208000005234 Granulosa Cell Tumor Diseases 0.000 claims description 2
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 claims description 2
- 206010043276 Teratoma Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000012018 Yolk sac tumor Diseases 0.000 claims description 2
- 201000008395 adenosquamous carcinoma Diseases 0.000 claims description 2
- 238000009809 bilateral salpingo-oophorectomy Methods 0.000 claims description 2
- NNTOJPXOCKCMKR-UHFFFAOYSA-N boron;pyridine Chemical compound [B].C1=CC=NC=C1 NNTOJPXOCKCMKR-UHFFFAOYSA-N 0.000 claims description 2
- 208000011892 carcinosarcoma of the corpus uteri Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 208000001991 endodermal sinus tumor Diseases 0.000 claims description 2
- 210000002919 epithelial cell Anatomy 0.000 claims description 2
- 230000003211 malignant effect Effects 0.000 claims description 2
- 230000002611 ovarian Effects 0.000 claims description 2
- 201000005292 ovarian small cell carcinoma Diseases 0.000 claims description 2
- 201000002524 peritoneal carcinoma Diseases 0.000 claims description 2
- 238000012163 sequencing technique Methods 0.000 claims description 2
- 208000019694 serous adenocarcinoma Diseases 0.000 claims description 2
- 208000000649 small cell carcinoma Diseases 0.000 claims description 2
- 208000001644 thecoma Diseases 0.000 claims description 2
- 238000009804 total hysterectomy Methods 0.000 claims description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 2
- 208000010576 undifferentiated carcinoma Diseases 0.000 claims description 2
- 201000005290 uterine carcinosarcoma Diseases 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims 1
- 230000009826 neoplastic cell growth Effects 0.000 claims 1
- 102100036561 WD repeat-containing protein 20 Human genes 0.000 description 32
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 239000002751 oligonucleotide probe Substances 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 2
- 208000034179 Neoplasms, Glandular and Epithelial Diseases 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 208000010932 epithelial neoplasm Diseases 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2009224.3A GB202009224D0 (en) | 2020-06-17 | 2020-06-17 | Methods for detecting and predicting cancer and/or cin3 |
| GB2009224.3 | 2020-06-17 | ||
| GBGB2107412.5A GB202107412D0 (en) | 2021-05-25 | 2021-05-25 | Methods for detecting and predicting cancer and/or CIN3 |
| GB2107412.5 | 2021-05-25 | ||
| PCT/GB2021/051536 WO2021255459A1 (en) | 2020-06-17 | 2021-06-17 | Methods for detecting and predicting cancer and/or cin3 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023530983A JP2023530983A (ja) | 2023-07-20 |
| JPWO2021255459A5 true JPWO2021255459A5 (https=) | 2024-06-20 |
| JP2023530983A5 JP2023530983A5 (https=) | 2024-06-20 |
Family
ID=76730905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022577444A Pending JP2023530983A (ja) | 2020-06-17 | 2021-06-17 | がんおよび／またはｃｉｎ３を検出および予測するための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240191302A1 (https=) |
| EP (1) | EP4168587A1 (https=) |
| JP (1) | JP2023530983A (https=) |
| KR (1) | KR20230024344A (https=) |
| AU (1) | AU2021291133A1 (https=) |
| BR (1) | BR112022025789A2 (https=) |
| CA (1) | CA3186997A1 (https=) |
| IL (1) | IL299142A (https=) |
| MX (1) | MX2022016100A (https=) |
| WO (1) | WO2021255459A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202315787D0 (en) * | 2023-10-16 | 2023-11-29 | Sola Diagnostics Gmbh | Method |
| GB202401477D0 (en) * | 2024-02-05 | 2024-03-20 | Sola Diagnostics Gmbh | Method |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013033627A2 (en) * | 2011-09-01 | 2013-03-07 | The Regents Of The University Of California | Diagnosis and treatment of arthritis using epigenetics |
| WO2016041010A1 (en) * | 2014-09-15 | 2016-03-24 | Garvan Institute Of Medical Research | Methods for diagnosis, prognosis and monitoring of breast cancer and reagents therefor |
| US9984201B2 (en) * | 2015-01-18 | 2018-05-29 | Youhealth Biotech, Limited | Method and system for determining cancer status |
| JP7299158B2 (ja) * | 2017-03-10 | 2023-06-27 | セルフ－スクリーン ベー．フェー． | Ｈｐｖ誘発浸潤がん、非ｈｐｖ誘発婦人科がん及び肛門性器がん、並びにその高度前駆病変を検出するためのメチル化分類子 |
| US12480164B2 (en) * | 2018-12-04 | 2025-11-25 | EpiMedTechGlobal (EMTG) | DNA methylation biomarkers for early detection of cervical cancer |
-
2021
- 2021-06-17 US US18/009,945 patent/US20240191302A1/en active Pending
- 2021-06-17 AU AU2021291133A patent/AU2021291133A1/en active Pending
- 2021-06-17 JP JP2022577444A patent/JP2023530983A/ja active Pending
- 2021-06-17 KR KR1020237000635A patent/KR20230024344A/ko active Pending
- 2021-06-17 WO PCT/GB2021/051536 patent/WO2021255459A1/en not_active Ceased
- 2021-06-17 BR BR112022025789A patent/BR112022025789A2/pt unknown
- 2021-06-17 EP EP21736665.7A patent/EP4168587A1/en active Pending
- 2021-06-17 MX MX2022016100A patent/MX2022016100A/es unknown
- 2021-06-17 CA CA3186997A patent/CA3186997A1/en active Pending
- 2021-06-17 IL IL299142A patent/IL299142A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6317354B2 (ja) | 血漿による胎児または腫瘍のメチロームの非侵襲的決定 | |
| US20220073994A1 (en) | Dna methylation biomarkers for early detection of cervical cancer | |
| WO2020029567A1 (zh) | 一种基于联合检测sdc2和sfrp2基因甲基化水平的结直肠癌早期诊断试剂 | |
| US20060265138A1 (en) | Expression profiling of tumours | |
| US20110144076A1 (en) | Preterm delivery diagnostic assay | |
| CN105316341A (zh) | 一种LncRNA及其在作为前列腺癌检测标记物或前列腺癌预后复发标记物中的应用 | |
| KR20090098677A (ko) | 폐암특이적 메틸화 마커 유전자를 이용한 폐암 검출방법 | |
| EP3034620A1 (en) | Compositions and methods for diagnosing thyroid cancer | |
| AU2016293381A1 (en) | Methods for diagnosis, prognosis and monitoring of breast cancer and reagents therefor | |
| JP4955385B2 (ja) | 結腸直腸細胞増殖障害の分析のための方法及び核酸 | |
| WO2013096661A1 (en) | Methylation biomarkers for ovarian cancer | |
| WO2024060775A1 (zh) | 新型的肿瘤检测标志物TAGMe及其应用 | |
| JP2022536180A (ja) | 乳がんを検出および予測するための方法 | |
| US20120201750A1 (en) | Serum biomarkers for melanoma metastasis | |
| CN109694907B (zh) | 一种无创产前筛查三体综合征的试剂盒及其应用 | |
| JP2023530983A (ja) | がんおよび／またはｃｉｎ３を検出および予測するための方法 | |
| JPWO2021255459A5 (https=) | ||
| JP2023534125A (ja) | がんを検出および予測する方法 | |
| CN115769078A (zh) | 用于卵巢癌评估的具有改良特异性与敏感性的组合物 | |
| CN106755563A (zh) | 生物标志物在诊断帕金森中的应用 | |
| TW201433638A (zh) | Hoxa9基因作為檢測肝癌生物標記的用途 | |
| CN117887848B (zh) | 一种卵巢良恶性病变的生物标志物及其应用 | |
| CN115698340A (zh) | 用glrb基因cpg甲基化变化来诊断结直肠癌、直肠癌或结直肠腺瘤的组合物和其应用 | |
| WO2025073218A1 (zh) | DNA甲基化标志物TAGMe-7的鉴定及其在肿瘤检测中的用途 | |
| WO2010085124A2 (ko) | 간암진단과 재발 및 생존 예측용 마커, 이를 포함한 키트 및 상기 마커를 이용한 간암환자 예후 예측 |